Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Viren Mehta
Industry has the tools to bring more and far better treatments to more people faster than ever, with much lower R&D cost and very little selling needed for these targeted therapies – a perfect prescription for slashing prices for global access while preserving profits, argues Viren Mehta of Mehta Partners LLC.
In his latest opinion piece, Viren Mehta fears the impact that ideologically motivated and protectionist actions around the world will have on the biopharma sector and ultimately on patients.
The transformation of the automotive world has many lessons for biopharma, especially on the regulatory front, believes Viren Mehta of Mehta Partners.
Viren Mehta of Mehta Partners LLC mulls the potential of blockchain, the rapidly evolving IT resource that secures every step in a business action.
Viren Mehta of Mehta Partners LLC ponders what the approval of Novartis gene therapy Zolgensma foreshadows, in terms of future therapies and pricing.
Regulators and policy makers are threatening the long-standing regulatory and patent protection structures that have helped prop the industry for many years. But pharma sustainability should in any case be based on innovation, writes Viren Mehta of Mehta Partners LLC.